title: Incidence and risk of xerosis with targeted anticancer therapies.
abstract: BACKGROUND
  Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained.
  
  
  OBJECTIVE
  We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs.
  
  
  METHODS
  The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models.
  
  
  RESULTS
  The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001).
  
  
  CONCLUSIONS
  The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions.
  
  
  CONCLUSIONS
  Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.
authors: Department of Dermatology, Naval Medical Center San Diego, San Diego, California.
authors: Johannah
authors: J
authors: Valentine
authors: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
authors: Viswanath Reddy
authors: VR
authors: Belum
authors: Department of Dermatology, Universidad del Rosario, Bogota, Colombia.
authors: Juanita
authors: J
authors: Duran
authors: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
authors: Kathryn
authors: K
authors: Ciccolini
authors: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
authors: Katja
authors: K
authors: Schindler
authors: Division of Hematology and Oncology, Stony Brook University Cancer Center, Stony Brook, New York; Division of Hematology and Oncology, Department of Medicine, Northport Veterans Affairs Medical Center, Northport, New York.
authors: Shenhong
authors: S
authors: Wu
authors: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: lacoutum@mskcc.org.
authors: Mario E
authors: ME
authors: Lacouture
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012306:Risk; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D006727:Hormone Antagonists; D009363:Neoplasm Proteins
keywords: Bcr-Abl; CD20; CD52; EGFR; HDAC; HER2; MEK; Raf; VEGFR; dry skin; incidence; mTOR; risk; xerosis